| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FIH1; PTH1 |
| Entrez GeneID | 5741 |
| clone | 8C5H9 |
| WB Predicted band size | 12.8kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PTH (AA: 32-115) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于PTH抗体的3篇代表性文献示例(内容为模拟概括，非真实引用)：
1. **《Parathyroid hormone autoantibodies in hypocalcemic patients: clinical implications》**
- **作者**: Smith A, et al.
- **摘要**: 研究报道了3例因PTH自身抗体导致严重低钙血症的病例，抗体干扰了PTH检测并阻断其生物活性，提示自身免疫性疾病中需警惕此类罕见病因。
2. **《Interference of endogenous antibodies in parathyroid hormone immunoassays: a multicenter study》**
- **作者**: Johnson R, et al.
- **摘要**: 通过分析1200例患者样本，发现约0.5%的病例存在PTH检测假性异常(高值或低值)，其中多数与异嗜性抗体或PTH特异性自身抗体相关，建议临床结合其他指标验证。
3. **《Comparison of second- and third-generation PTH assays in chronic kidney disease patients》**
- **作者**: Lee C, et al.
- **摘要**: 比较不同代际PTH检测方法(如全段PTH与生物活性PTH测定)在肾病患者中的差异，发现某些检测可能因抗体交叉反应导致结果偏差，影响继发性甲旁亢的诊断准确性。
---
**说明**：
1. 真实文献需通过PubMed/Google Scholar检索关键词如 **"PTH antibody interference"** 或 **"parathyroid hormone autoantibodies"** 获取。
2. 临床相关研究多聚焦于抗体对检测的干扰机制(如假性PTH升高/降低)或自身抗体引发的代谢异常(如低钙血症)。
3. 建议补充检索方向：甲状旁腺功能减退症、多发性内分泌自身免疫综合征等疾病中的PTH抗体研究。
Parathyroid hormone (PTH) antibodies are specialized immunoglobulins designed to target and bind to PTH, a peptide hormone produced by the parathyroid glands. PTH plays a critical role in calcium and phosphorus homeostasis by regulating bone resorption, renal calcium reabsorption, and vitamin D metabolism. PTH antibodies are primarily utilized in research and clinical diagnostics to measure PTH levels in serum or plasma, aiding in the diagnosis and management of disorders like hyperparathyroidism, hypoparathyroidism, and chronic kidney disease-related mineral imbalances.
These antibodies are classified as monoclonal or polyclonal, depending on their specificity and application. Monoclonal antibodies, generated from identical immune cells, offer high specificity for distinct PTH epitopes, while polyclonal antibodies recognize multiple epitopes, enhancing detection sensitivity. In immunoassays (e.g., ELISA, chemiluminescence), PTH antibodies help differentiate intact PTH (biologically active) from inactive fragments, improving diagnostic accuracy.
Beyond diagnostics, PTH antibodies are explored therapeutically. For instance, antibody-based therapies targeting PTH or its receptor are under investigation for conditions like osteoporosis or hypercalcemia. However, their clinical use remains limited compared to diagnostic applications. Recent advances include engineered antibody fragments for targeted drug delivery or imaging in parathyroid-related pathologies. Challenges persist in minimizing cross-reactivity with PTH-related peptides and ensuring stability in assay environments. Overall, PTH antibodies remain indispensable tools for understanding and managing calcium-related disorders.
×
